01—Abstract
Summary
Summary of the 8-K filed August 14, 2025. Cited figures are marked; the original filing is the authoritative source.
Gilead Sciences, Inc. (GILD) announced a key leadership change in its financial reporting structure through an 8-K filing on August 13, 2025.
The company has appointed Erin Burkhart as the new Senior Vice President, Controllership and principal accounting officer, effective September 22, 2025. This appointment brings a seasoned financial executive with extensive experience in the biotechnology and pharmaceutical sectors to a critical role within Gilead's finance organization. Ms. Burkhart's prior roles include Group Vice President and Chief Accounting Officer at BioMarin Pharmaceutical Inc., and various senior accounting and finance positions at Eli Lilly and Company.
Her background in public accounting with major firms and her CPA certification underscore her qualifications for overseeing Gilead's financial reporting. This transition marks a change in leadership for the principal accounting officer role, with Diane E. Wilfong stepping down from her interim position.
02—Key points
Key Highlights
- Gilead Sciences (GILD) appointed Erin Burkhart as Senior Vice President, Controllership and principal accounting officer.
- The appointment is effective September 22, 2025.
- Ms. Burkhart brings significant experience from BioMarin Pharmaceutical Inc. where she served as Group Vice President and Chief Accounting Officer.
- Her previous tenure includes roles of increasing responsibility in accounting and finance at Eli Lilly and Company.
- Ms. Burkhart is a licensed certified public accountant (CPA) with a strong foundation in public accounting.
- Diane E. Wilfong will step down from her interim role as Controller and principal accounting officer.
- This executive appointment is a material event disclosed via an 8-K filing.
03—Questions
Frequently Asked Questions
Who is Erin Burkhart and what is her new role at Gilead?
Erin Burkhart has been appointed as the new Senior Vice President, Controllership and principal accounting officer for Gilead Sciences, Inc. She is a seasoned financial executive with extensive experience in the pharmaceutical and biotechnology industries, including previous leadership roles at BioMarin Pharmaceutical Inc. and Eli Lilly and Company.
When does this change take effect?
The appointment of Erin Burkhart is effective as of September 22, 2025.
What is the significance of this appointment for Gilead?
This appointment is significant as it fills a key leadership position responsible for the company's financial reporting and controllership. Ms. Burkhart's expertise is expected to strengthen Gilead's financial oversight and reporting processes.
Who is Ms. Burkhart replacing in this role?
Ms. Burkhart is succeeding Diane E. Wilfong, who will be stepping down from her position as interim Controller and principal accounting officer as of the transition date.
04—Continue